It enhances the stability, hydrophobicity, and aggregation potential of the Aβ peptide underlying β-amyloid formation in Alzheimer’s disease (34); it forms pGlu79-α-synuclein, which promotes oligomerization and synucleinopathies in Parkinson’s disease (35, 36); and the modification of CD47 directly influences interactions with SIRPα to modulate the immunological surveillance mechanisms essential for the removal of cancer and senescent cells (37, 38). This evidence concerns the gene SIRPA and early-onset autosomal dominant Alzheimer disease.